CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international...

Corline Biomedical AB: Tecknar samarbetsavtal för CHS™-coatning av bypassgraft med ambition att starta kliniska studier 2023 Corline har tecknat ett utvecklings- och samarbetsavtal med en europeisk leverantör av kärlgrafter för bypassoperationer som används vid kirurgi för patienter med hjärtinfarkt. Avtalet reglerar...